Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
IVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.53 - $4.50
Previous CloseN/A
Volume917.00
Average Volume (3M)8.83K
Market Cap
$233.86M
Enterprise Value$200.90M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 26, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding95,662,390
10 Day Avg. Volume6,966
30 Day Avg. Volume8,834
Standard Deviation0.17
R-Squared0.07
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.88
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14.80Price Target Upside421.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Inventiva News
PremiumCompany Announcements
Inventiva and Hepalys Initiate Phase 1 Trial for Lanifibranor in Japan
PremiumCompany Announcements
Inventiva S.A. Boosts Capital with New Share and Warrant Issuance---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAnalysts are bullish on the Phase 3 NATIV3 trial in MASH, driving potential US and EU approval.
Financial ResourcesThe company is expected to access a second tranche of funding, which will remove any funding concerns and support development of lanifibranor to the Phase III readout.
FinancingRecent financing agreement extends cash runway, providing funds for Phase 3 development.
Bears Say
Clinical Trial RisksKey risks to the rating and price target include clinical trial failures or equivocal results, meaningful delays to expected development or regulatory timelines, and inability to access equity capital markets at reasonable terms.
Weight Gain ConcernsWeight gain from lanifibranor is a potential concern for physicians, despite being manageable with SGLT2 inhibitor combination.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
5.01% Other Institutional Investors
94.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $1.53 and its highest was $4.50 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $233.86M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Mar 26, 2025 which is in 32 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Sep 25, 2024. The company reported -$0.872 earnings per share for the quarter, missing the consensus estimate of -$0.783 by -$0.089.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.61.
How many shares outstanding does Inventiva have?
Inventiva has 95,662,390 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$0.872 in its last earnings report, missing expectations of -$0.783. Following the earnings report the stock price went down -17.13%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
---
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.80 (421.13% Upside)
$14.80 (421.13% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.45%
12-Months-Change
Fundamentals
Return on Equity
344.74%
Trailing 12-Months
Asset Growth
-45.49%
Trailing 12-Months
Company Description
Inventiva
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis and rare diseases. All the company's operations are located in France.
---
IVA Stock 12 Month Forecast
Average Price Target
$14.80
▲(421.13% Upside)
Technical Analysis
Best Analysts Covering IVA
1 Year
1 Year Success Rate
5/22 ratings generated profit
1 Year Average Return
-30.92%
reiterated a buy rating 24 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 22.73% of your transactions generating a profit, with an average return of -30.92% per trade.
---